Drug Metabolism Group

Total Page:16

File Type:pdf, Size:1020Kb

Drug Metabolism Group Br. J. Cancer (1985), 52, 409-468 Twenty-Sixth Annual General Meeting of the British Association for Cancer Research* (in conjunction with the European Organization for Research and Treatment for Cancer -Pharmacokinetics and Metabolism Group and the Drug Metabolism Group) (Incorporating Symposia on 'Reactive intermediates in drug metabolism and carcinogenicity', 'New directions in the therapy of cancer', 'The early clinical trials of novel antitumour agents'; the 1985 Walter Hubert Lecture: and the West Midlands Oncology Association Guest Lecture) March 24-27, 1985. Held at Aston University, Birmingham, UK. Abstracts of invited paperst Symposium: aromatase, as potential therapeutic agents in the treatment of oestrogen-dependent tumours. Reactive intermediates in drug metabolism and carcinogenicity The role of reactive electrophiles in biological activity The generation and fate of free radicals in intact and toxicity cells S.D. Nelson S. Orrenius Department of Medicinal Chemistry BG-20, Department of Toxicology, Karolinska Institutet, University of Washington, Seattle, WA 98195 USA. S-104 01 Stockholm, Sweden. In the last two decades it has become apparent that There is increasing evidence that organic radicals as toxic manifestations of many chemicals arise from well as oxygen radicals may cause acute cell injury covalent interactions of either the compounds and also be involved in the initiation and themselves or more commonly their metabolites promotion of tumor formation. In the cell, with tissue macromolecules. Identification of the peroxidase-mediated metabolism of various drugs products of covalent interaction has demonstrated and carcinogens, and one-electron reduction of that the reactive forms are generally electrophilic. many quinones, e.g. menadione, can be a source of The nature of several classes of electrophiles will be generation of both types of radicals. Their briefly described in regard to mechanisms of subsequent interaction with reduced glutathione formation and reaction with nucleophiles. Ongoing (GSH) results in the formation of either glutathione studies in my laboratory on the pathogenesis of S-conjugates or glutathione disulfide (GSSG); the toxicities caused by a halogenated alkyl phosphate latter may occur in part by dimerization of and a terpene will illustrate procedures that are glutathionyl (GS ) radicals generated during the used to define mechanisms of reactive metabolite interaction of organic free radicals with GSH. Since formation. Acetaminophen metabolism will be both glutathione S-conjugates and GSSG are discussed to highlight the complex nature of actively excreted by the cell, this may result in GSH interactions of some electrophiles with tissue depletion and, if the production of free radicals nucleophiles. And, finally, our knowledge of continues, their attack on other cellular nucleophilic reactive electrophiles will be applied to describe the groups, including those in various proteins and preparation of suicide substrates of the enzyme, DNA. This may in turn result in either acute or chronic cell damage. Thus, depletion of protein *Enquiries to the BACR Secretariat c/o Institute of thiols appears to be intimately associated with the Biology, 20 Queensberry Place, London SW7 2DZ. development of menadione-induced cytotoxicity in tReprints of these abstracts are not available - Ed. hepatocytes, possibly via a perturbation of their tThis issue pp. 239-302. Ca2+ homeostasis. 410 AGM BACR ABSTRACTS The role of glutathione in the detoxication of enabled us to make some progress towards electrophilic, peroxy and free radical metabolites determining enzyme mechanisms in vivo. These B. Ketterer results throw much new light on the biochemistry of formaldehyde. More importantly they Cancer Research Campaign Molecular Toxicology demonstrate that these techniques are applicable to Research Group, Middlesex Hospital Medical any xenobiotic which can be labelled and handled School, London WIP 7PN, UK. at the millimolar level, and to any organism which The oxidation of xenobiotics may give rise to can be put into an NMR spectrometer. electrophiles, and by-products of oxygen utilization such as phospholipid hydroperoxides both of which are potentially cytotoxic, and may be detoxified by Symposium: glutathione (GSH) which is a nucleophile and a New Directions reducing agent. in the Therapy of GSH reacts poorly with hard electrophiles, but Cancer well with soft electrophiles, and a family of GSH Oncogenes in cancer therapy transferase enzymes has the capacity to catalyse some if not all these reactions. Such catalysis is an K. Sikora important determinant of the fate of hard Ludwig Institute for Cancer Research, MRC Centre, electrophiles which tend to be genotoxic. On the Hills Road, Cambridge CB2 2QH, UK. other hand if good substrates are present at high The central problem in cancer therapy is the poor doses catalysis itself may cause toxicity due to GSH selectivity of current systemic agents against the depletion. The capacity of different tissues to common solid tumours. The demonstration that detoxify electrophiles varies: it depends on their unique segments of DNA; constant in location and GSH content, the qualitative and quantitative conserved in evolution are involved in growth distribution of GSH transferase isoenzymes in each control opens new avenues for basic and clinical tissue, and the nature of the electrophiles research. The functions of the products of these themselves. genes need to be elucidated. Examples of growth Reduction of phospholipid hydroperoxides by control functions include homology to growth GSH requires the concerted action of factors; surface receptors; protein kinases and cell phospholipase A2 and a range of GSH peroxidases cycle control proteins. From DNA sequence data (the latter utilize free fatty acid hydroperoxides as peptides predicted to be exposed within the intact substrates). molecule can be constructed and used to produce In principle GSH might act as a trap for oxidising monoclonal antibodies to oncogene products. Such free radicals and also free radicals resulting from antibodies have now been successfully used to one electron oxidations of xenobiotics. This has yet demonstrate the intracellular localisation of gene to be demonstrated incontrovertibly because the products as well as the cell cycle regulatory role of resultant thiyl free radical is so difficult to detect. the c-myc protein in vitro. By having a battery of antibodies against the different gene products their direct clinical application for diagnosis and Observing xenobiotic metabolism by in vivo NMR prognosis has become a reality. Immunohistology J.K.M. Sanders and flow cytometry permit the geographical and University Chemical Laboratory, Lensfield Road, quantitative analysis of function in normal and Cambridge CB2 JEW, UK. neoplastic tissues. Furthermore by purification and biochemical analysis the molecular basis for their Carbon, deuterium and proton NMR spectroscopy action can be elucidated. It is likely that by the end have been used to monitor the metabolism of of the decade new drugs that inhibit oncoprotein labelled formaldehyde by a variety of bacterial and function will be available for clinical trial. plant cell preparations. Depending on circumstances, the timescale per spectrum may be as short as 2 min. The rate of metabolism has been Clinical correlates of in vitro studies of small cell correlated with growth and experimental lung cancer conditions, and the metabolism has been shown to D.N. Carney be a detoxifying process in competition with lethal chemistry. The structures of several metabolic Mater Hospital and Saint Lukes Hospital, Dublin, products have been determined in these living Eire. cultures, and have been shown to include A panel of 52 cell lines (CL) derived from patients incorporation, oxidation and reduction products. (pts) with small cell lung cancer (SCLC) have been NMR observations using deuterium NMR have analysed for morphology, cloning efficiency (CE), AGM BACR ABSTRACTS 411 radiation sensitivity, and the expression of a panel facilities at Birkbeck were then used to construct a of biomarkers including L-dopa decarboxylase stereochemically-sensible model for the ATP- (DDC), bombesin (BN), neuron specific enolase binding site of v-src. The model may prove useful (NSE), and creatine kinase BB (CK-BB). Many CL for the design of inhibitors as clinical agents. have been analysed for the c-myc and N-myc (Stemnberg & Taylor, 1984, FEBS Lett., 175, 387). oncogenes. Results of these studies show that SCLC CL can be subdivided into 3 groups: (1) Multipotent CL (N= 2) which in vitro undergo The dependence of cancer cells on growth factors as simultaneous differentiation into SCLC, adeno and a target for chemotherapy squamous cell carcinoma providing evidence for a P. Alexander common stem cell for all types of lung cancer: (2) CRC Medical Oncology Unit, University of Classic SCLC CL (N= 35, 70%) grow as tight Southampton, Southampton General Hospital, aggregates of floating cells, have a low CE (1-5%); Southampton S09 4XY, UK. a long doubling time (DT) (72h); express elevated levels of all 4 biomarkers, and are radiosensitive. Evidence is accumulating that for cancer cells as for (3) Variant SCLC CL (N= 15, 30%) grow as loose normal cells proliferation is dependent on a aggregates; have a high CE (10-30%) a short DT sequence of interactions between receptors on the (26 h), are radioresistant, and lack DDC and BN. outside of the cell membrane and polypeptide Amplified
Recommended publications
  • WO 2013/134349 Al 12 September 2013 (12.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/134349 Al 12 September 2013 (12.09.2013) P O P C T (51) International Patent Classification: (74) Agents: CASSIDY, Timothy, A. et al; Dority & Man A61K 45/06 (2006.01) A61P 35/00 (2006.01) ning, P.A., P O Box 1449, Greenville, SC 29602-1449 A61K 9/50 (2006.01) A61K 47/48 (2006.01) (US). A61K 9/51 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US20 13/029294 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 6 March 2013 (06.03.2013) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (30) Priority Data: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, 61/607,036 6 March 2012 (06.03.2012) US TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 13/784,930 5 March 2013 (05.03.2013) US ZM, ZW.
    [Show full text]
  • Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S
    ANTICANCER RESEARCH 37 : 3413-3421 (2017) doi:10.21873/anticanres.11708 Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide KAVINDRA NATH 1, DAVID S. NELSON 1, JEFFREY ROMAN 1, MARY E. PUTT 2, SEUNG-CHEOL LEE 1, DENNIS B. LEEPER 3 and JERRY D. GLICKSON 1 Departments of 1Radiology and 2Biostatistics & Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, U.S.A.; 3Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, U.S.A. Abstract. Background/Aim: Since temozolomide (TMZ) is stages. However, following recurrence with metastasis, the activated under alkaline conditions, we expected lonidamine prognosis is poor. Mutationally-activated BRAF is found in (LND) to have no effect or perhaps diminish its activity, but 40-60% of all melanomas with most common substitution of initial results suggest it may actually enhance either or both valine to glutamic acid at codon 600 (p. V600E) (3). Overall short- and long-term activity of TMZ in melanoma xenografts. survival is approaching two years using agents that target this Materials and Methods: Cohorts of 5 mice with subcutaneous mutation (4, 5). MEK, RAS and other signal transduction xenografts ~5 mm in diameter were treated with saline inhibitors, in combination with mutant BRAF inhibitors, have (control (CTRL)), LND only, TMZ only or LND followed by been used to deal with melanoma resistance to these agents TMZ at t=40 min (time required for maximal tumor (6). Treatment with anti-programmed death-1 (PD-1) acidification). Results: Mean tumor volume for LND+TMZ for checkpoint inhibitor immunotherapy currently produces the period between 6 and 26 days was reduced compared to durable response in about 25% of melanoma patients (7-10).
    [Show full text]
  • Prospects for NK Cell Therapy of Sarcoma
    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; [email protected] 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: [email protected] (R.Z.); [email protected] (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
    [Show full text]
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • The Synergistic Anti-Neoplastic Activity of Combinations of Mitomycins with Either 6-Thioguanine Or @.-F1uorouracip
    CANCER RESEARCH VOLUME 25 OCTOBER 1965 NUMBER 9 The Synergistic Anti-neoplastic Activity of Combinations of Mitomycins with Either 6-Thioguanine or @.-F1uorouraciP ALAN C. SARTORELLI AND BARBARA A. BOOTH Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut SUMI@1ARY Mitomycin C or porfiromycin (methyl mitomycin) in combination with either 6- thioguanine or 5-fluorouracil produced synergistic inhibition of the growth of both Sar coma 180 and Lymphoma L1210 ascites cell neoplasms. i\Iitomycin C and porfiromy cm possessed the same therapeutic index in the L1210 lymphoma system, but mitomycin C was about 5 times more potent. Doses of mitomycin C that induced pro nounced inhibition of thymidine-3H incorporation into deoxyribonucleic acid (DNA) did not decrease the average DNA content of treated cells. The degree of inhibition of ribonucleic acid (RNA) synthesis by mitomycin C was less pronounced than that of DNA, and lysine-1-'4C fixation into residual protein was insensitive to the antibiotic. 6-Thioguanine induced a marked depression in the rate of incorporation of thymidine 3H and orotic acid-6-'4C into DNA and RNA, respectively. The combination of these agents produced subadditive to additive inhibition of the formation of nucleic acids and also caused inhibition of protein synthesis; incorporation of thymidine into DNA ap peared to be the metabolic path most sensitive to the combination of these agents. Measurement of thymidine kinase and thymidylate kinase activity in cells treated with these agents indicated that these enzymes were relatively resistant to the action of mi tomycin C ; however, some inhibition of thymidylate kinase activity was induced by the thioguanine treatment.
    [Show full text]
  • Activity of Mitozolomide (NSC 353451), a New Imidazotetrazine, Against Xenografts from Human Melanomas, Sarcomas, and Lung and Colon Carcinomas
    (CANCER RESEARCH 45, 1778-1786, April 1985] Activity of Mitozolomide (NSC 353451), a New Imidazotetrazine, against Xenografts from Human Melanomas, Sarcomas, and Lung and Colon Carcinomas Oy stein Fodstad, ' Steina r Aamdal,2 Alexander Pihl, and Michael R. Boyd Norsk Hydros Institute for Cancer Research, Montebello, Oslo 3, Norway [0. F., S. Aa., A. P.] and Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20205 [0. F., M. R. B.¡ ABSTRACT In this investigation, we first tested the anticancer activity of mitozolomide against cells from different xenografted cancers in The chemosensitivity of human tumor xenografts to mitozo- a HTCF assay in vitro. When a pronounced inhibition of colony lomide, 8-carbamoyl-3-{2-chloroethyl)imidazo[5-1 -d]-1,2,3,5-te- formation was observed, we next examined in the HTCF assay trazin-4(3H)-one, was studied in 3 different assay systems. In the efficiency of the drug on a panel of tumors for each histolog concentrations of 1 to 500 ¿/g/ml,mitozolomide completely inhib ical type. Since in vitro test systems have inherent limitations ited the colony-forming ability in soft agar of cell suspensions (23), we also measured the in vivo effect of mitozolomide on the from sarcomas, melanomas, lung and colon cancers, and a same tumors, using the 6-day subrenal capsule assay in immu- mammary carcinoma. When a panel of tumors of the different nocompetent mice (1-3), as well as s.c. growing tumors in histological types was tested for its sensitivity to mitozolomide athymic, nude mice (5-7, 10, 16, 18).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Interactions of Antitumor Triazoloacridinones with DNA
    Vol. 54 No. 2/2007, 297–306 on-line at: www.actabp.pl Regular paper Interactions of antitumor triazoloacridinones with DNA * Marcin Koba and Jerzy Konopa Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, Gdańsk, Poland Received: 12 February, 2007; revised: 20 March, 2007; accepted: 21 March, 2007 available on-line: 19 April, 2007 Triazoloacridinones (TA) are a new group of potent antitumor compounds, from which the most active derivative, C-1305, has been selected for extended preclinical trials. This study investi- gated the mechanism of TA binding to DNA. Initially, for selected six TA derivatives differing in chemical structures as well as cytotoxicity and antitumor activity, the capability of noncova- lent DNA binding was analyzed. We showed that all triazoloacridinones studied stabilized the DNA duplex at a low-concentration buffer but not at a salt concentration corresponding to that in cells. DNA viscometric studies suggested that intercalation to DNA did not play a major role in the mechanism of the cytotoxic action of TA. Studies involving cultured cells revealed that triazoloacridinone C-1305 after previous metabolic activation induced the formation of interstrand crosslinks in DNA of some tumor and fibroblast cells in a dose dependent manner. However, the detection of crosslink formation was possible only when the activity of topoisomerase II in cells was lowered. Furthermore, it was impossible to validate the relevance of the ability to crosslink DNA to biological activity of TA derivatives. Keywords: triazoloacridinones, DNA intercalation, DNA interstrand crosslinks, structure–activity relationship, biological activity, metabolic activation INTRODUCTION Previous investigations demonstrated that triazoloacridinones inhibited cleavable complexes of Triazoloacridinones (TA) (see Table 1, for topoisomerase II–DNA and also the catalytic activity structures) are a class of antitumor agents synthe- of this enzyme (Skladanowski et al., 1999; Lemke et sized in our laboratory (Cholody et al., 1990).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti Et Al
    US008580267B2 (12) United States Patent (10) Patent No.: US 8,580,267 B2 Pedretti et al. (45) Date of Patent: Nov. 12, 2013 (54) IMMUNOCYTOKINES FORTUMOUR (56) References Cited THERAPY WITH CHEMOTHERAPEUTIC AGENTS FOREIGN PATENT DOCUMENTS (75) Inventors: Marta Pedretti, Zurich (CH): Dario WO O2/O59264 8, 2002 WO O3,O93478 11, 2003 Neri, Buchs (CH) WO 2004/OO2528 1, 2004 WO 2006/026020 3, 2006 (73) Assignee: Philogen S.p.A., Siena (IT) WO 2006/050834 5, 2006 WO 2007/128563 11, 2007 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Paul, William, Fundamental Immunology, 3rd Edition, Raven Press, New York, 1993, pp. 292-295.* (21) Appl. No.: 13/139,655 Vajdos et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning 1-1. mutagenesis. J. Mol. Biol. 320:415-428, 2002.* (22) PCT Filed: Dec. 14, 2009 Bartolomei, M., et al. “Combined treatment of glioblastomapatients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and (86). PCT No.: PCT/EP2009/008920 temozolomide.” QJNuclMed Mol Imaging. Sep. 2004:48(3):220-8. S371 (c)(1) Marlind, J., et al. "Antibody-mediated delivery of interleukin-2 to the (2), (4) Date. Jun. 14, 2011 Stroma of breast cancer strongly enhances the potency of chemo s 9 therapy” Clin Cancer Res. Oct. 15, 2008;14(20):6515-24. Brack, S.S., et al. “Tumor-targeting properties of novel antibodies (87) PCT Pub. No.: WO2010/078916 specific to the large isoform oftenascin-C.” Clin Cancer Res.
    [Show full text]
  • The Emerging Role of Paclitaxel in Breast Cancer Therapy1
    Vol. 1, 247-256, March 1995 Clinical Cancer Research 247 Minireview The Emerging Role of Paclitaxel in Breast Cancer Therapy1 Andrew D. Seidman2 overexpressing subline of MCF-7 cells appears to result in the Breast and Gynecological Oncology Service, Memorial Sloan- development of 4.4-fold less resistance (6). Furthermore, in Kettering Cancer Center, New York, New York 10021 paclitaxel-resistant cells, the ratio of soluble to polymerized tubulin is greater than that observed in sensitive cells (7). Introduction Ongoing investigation should clarify the relationship between Multiple chemotherapeutic agents and regimens exist with tubulin alterations and resistance to taxanes. documented antitumor activity against breast cancer; however, In parallel with the development of clinical trials of paclitaxel- less than one in five patients with stage IV breast cancer are alive based combination regimens, in vivo and in vitro studies have 5 years from the first detection of distant metastases (1). Although examined combinations for cytotoxicity in several systems. In vitro improved response proportions have been observed, overall sur- studies in human MCF-7 breast carcinoma cells exposed to a LD vival for patients with metastatic breast cancer has not been sig- of paclitaxel for 24 h followed by a 1-h incubation with varying nificantly improved by the progress of the past three decades. Furthermore, despite the proven magnitude of benefit of adjuvant concentrations of doxorubicin showed less than additive cytotox- icity for the combination of paclitaxel and doxorubicin (8). On the systemic therapy in reducing the risk of recurrence (2), a significant fraction of patients with early stage breast cancer still will relapse other hand, when an AlT cell viability assay was used, others have and ultimately die of metastatic disease.
    [Show full text]
  • Bendamustine in Combination with Gemcitabine and Vinorelbine Is An
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio istituzionale della ricerca - Università di Modena e Reggio Emilia VOLUME 34 • NUMBER 27 • SEPTEMBER 20, 2016 JOURNAL OF CLINICAL ONCOLOGY ORIGINAL REPORT Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Flavia Salvi, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, and Carmelo Carlo-Stella Armando Santoro, Rita Mazza, Luca Castagna, Laura Giordano, and Carmelo ABSTRACT Carlo-Stella, Humanitas Cancer Center; Armando Santoro, Humanitas University, Purpose Rozzano; Alessandro Pulsoni and Giorgia This multicenter, open-label, phase II study evaluated the combination of bendamustine, gemci- Annechini, Sapienza University, Rome; tabine, and vinorelbine (BeGEV) as induction therapy before autologous stem-cell transplantation Alessandro Re, Antonella Anastasia, and (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (HL). Annalisa Peli, Spedali Civili, Brescia; Maurizio Bonfichi and Manuel Gotti, Patients and Methods Istituto di Ricovero e Cura a Carattere Patients with HL who were refractory to or had relapsed after one previous chemotherapy line were Scientifico (IRCCS) Policlinico San Matteo, eligible. The primary end point was complete response (CR) rate after four cycles of therapy. Pavia; Vittorio Ruggero Zilioli, Niguarda Ca’ Granda Hospital; Carmelo Carlo-Stella, Secondary end points were: overall response rate, stem-cell mobilization activity, and toxicity.
    [Show full text]
  • Ep 2569287 B1
    (19) TZZ _T (11) EP 2 569 287 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 413/04 (2006.01) C07D 239/46 (2006.01) 09.07.2014 Bulletin 2014/28 (86) International application number: (21) Application number: 11731562.2 PCT/US2011/036245 (22) Date of filing: 12.05.2011 (87) International publication number: WO 2011/143425 (17.11.2011 Gazette 2011/46) (54) COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERBINDUNGEN ALS HEMMER DER ATR-KINASE COMPOSÉS UTILISABLES EN TANT QU’INHIBITEURS DE LA KINASE ATR (84) Designated Contracting States: • VIRANI, Aniza, Nizarali AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abingdon GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Oxfordshire OX144RY (GB) PL PT RO RS SE SI SK SM TR • REAPER, Philip, Michael Abingdon (30) Priority: 12.05.2010 US 333869 P Oxfordshire OX144RY (GB) (43) Date of publication of application: (74) Representative: Coles, Andrea Birgit et al 20.03.2013 Bulletin 2013/12 Kilburn & Strode LLP 20 Red Lion Street (73) Proprietor: Vertex Pharmaceuticals Inc. London WC1R 4PJ (GB) Boston, MA 02210 (US) (56) References cited: (72) Inventors: WO-A1-2010/054398 WO-A1-2010/071837 • CHARRIER, Jean-Damien Abingdon • C. A. HALL-JACKSON: "ATR is a caffeine- Oxfordshire OX144RY (GB) sensitive, DNA-activated protein kinase with a • DURRANT, Steven, John substrate specificity distinct from DNA-PK", Abingdon ONCOGENE, vol. 18, 1999, pages 6707-6713, Oxfordshire OX144RY (GB) XP002665425, cited in the application • KNEGTEL, Ronald, Marcellus Alphonsus Abingdon Oxfordshire OX144RY (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]